When Emma Walmsley was revealed as the successor to Sir Andrew Witty as CEO of GlaxoSmithKline PLC, it was clear the board had opted to secure Witty's volume-first growth strategy for the company that was launched in 2015.
But the world looks quite different in 2017 than it did in 2015. What does this mean for Walmsley and...